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Abstract
Background: Mutations in the gene ATP7B cause Wilson disease, a copper storage disorder with a high
phenotypic and genetic heterogeneity. We aimed to evaluate whether ‘severe’ protein-truncating ATP7B mutations
(SMs) are associated with low serum ceruloplasmin oxidase activities and an early age of onset when compared to
missense mutations (MMs).
Methods: The clinical phenotype of 59 genetically confirmed WD patients was analyzed retrospectively. Serum
ceruloplasmin was measured by its oxidase activity with o-dianisidine dihydrochloride as substrate and
immunologically.
Results: Thirty-nine patients had two MMs, 15 had the genotype SM/MM, and 5 patients had two SMs on their
ATP7B alleles. Enzymatic and immunologic serum ceruloplasmin levels differed significantly between the three
groups (P < 0.001 and P < 0.01, respectively). The lowest levels were measured in patients with two SMs (0.0 U/L;
IQR, 0.0-0.0 U/L and 0.02 g/L; IQR, 0.01-0.02 g/L, respectively) and the highest in patients with two MMs (17.8 U/L;
IQR, 5.8-35.1 U/L and 0.11 g/L; IQR,0.10-0.17 g/L, respectively). The age of onset was also significantly different
between the three patient groups (P < 0.05), with SM/SM patients showing the earliest onset (13 years; IQR, 9-13
years) and patients with two MMs showing the latest onset (22 years; IQR, 14-27 years). By ROC curve analysis a
ceruloplasmin oxidase level ≤ 5 U/L can predict the presence of at least one SM with a sensitivity of 80% and a
specificity of 79.5%.
Conclusions: In our German study cohort truncating ATP7B mutations were associated with lower ceruloplasmin
serum oxidase levels and an earlier age of onset when compared to MMs. Measurement of serum ceruloplasmin
oxidase might help to predict presence of truncating ATP7B mutations and might facilitate the mutation analysis.
Background
Wilson disease (WD) is a rare, autosomal-recessively
inherited disorder of copper metabolism due to muta-
tions of the WD gene ATP7B [1,2]. The WD gene
ATP7B codes for a membrane-bound, copper-binding
protein that is expressed primarily in the liver [1,2]. Dis-
ease causing mutations in the ATP7B gene result in a
reduced biliary copper excretion [3]. WD is clinically
characterized by hepatic (e.g. liver cirrhosis) and
neurological manifestations related to the accumulation
of copper in the liver and the brain [3]. The onset of
signs and symptoms of WD typically is in childhood
and young adulthood but may even be much later [4].
In addition to copper accumulation the disturbed
function of ATP7B results in an impaired incorporation
of copper into apoceruloplasmin leading to the forma-
tion of an unstable ceruloplasmin which is rapidly
degraded [5]. Although this might be of minor impor-
tance in copper homeostasis, impaired holo-ceruloplas-
min synthesis is of diagnostic relevance as serum
ceruloplasmin concentration is considered a useful
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plasmin concentration is determined in most routine
laboratories immunologically, but can also be measured
enzymatically by its oxidase activity [7-9]. Recently, we
could show that measurement of the enzymatic oxidase
activity of serum ceruloplasmin with o-dianisidine dihy-
drochloride as substrate is of greater diagnostic value
than its immunologically measured concentration [10].
WD typically begins with a pre-symptomatic period,
during which copper accumulation in the liver leads to
subclinical hepatitis, and progresses to liver cirrhosis
and development of neuropsychiatric symptoms. The
type of hepatic and neurological symptoms can be
highly variable. The wide variation in the clinical pheno-
type of WD has still to be elucidated and may be related
to the ATP7B genotype. Although some authors have
tried to establish whether the ATP7B genotype deter-
mines the phenotype of the disease, the data are con-
flicting and no definitive association has been
established [11-14]. Reasons for the difficulties in asses-
sing genotype-phenotype correlations in WD are the
high genetic heterogeneity with the large number of
mutations and the rareness of the disease. About 300
mutations have been described (Wilson Disease Muta-
tion Database compiled by the Department of Medical
Genetics at the University of Alberta is accessible at the
web page http://www.wilsondisease.med.ualberta.ca/
database.asp). Protein-truncating nonsense mutations
and frameshift mutations are presumed to have a differ-
ent impact on the functional impairment of the ATP7B
protein than missense mutations and are hypothetically
more ‘severe’ mutations than these. In line with this
assumption, a more severe impairment of copper meta-
bolism parameters and an earlier age of disease onset in
WD patients with protein-truncating mutations could
recently be demonstrated for different European cohorts
[15,16].
The aim of our study conducted in a German WD
cohort was to evaluate whether the type of mutation
correlates (1) with serum ceruloplasmin levels measured
enzymatically with o-dianisidine as substrate, and (2)
with age of onset of the disease.
Methods
Patients
One hundred and ten consecutive patients with WD (45
men and 65 women), all referred to the Department of
Gastroenterology at the University of Heidelberg
between 04/2006 and 04/2008, were screened. In all
screened patients diagnosis of WD was based on the
WD score published previously [17] and mutation analy-
sis was performed as described previously [4]. In 62 of
these screened patients mutation analysis revealed a
homozygous or compound heterozygous ATP7B
mutation. Exclusion criteria were an acute hepatitis (n =
0), pregnancy (n = 0), and intake of anticonceptive pills
(n = 3) as ceruloplasmin may be elevated in inflamma-
tory stages, during pregnancy, and in response to exo-
genous administration of estrogens [18,19]. After
exclusion of all women taking anticonceptive pills the
remaining 59 genetically-confirmed subjects (25 men, 34
women) were enrolled into the study. Of these 59
patients, 4 were treatment naïve and 55 were treated
with D-penicillamine, trientine, or zinc salts.
The study protocol was approved by the ethics com-
mittee of the University of Heidelberg and all patients
gave written informed consent.
Laboratory methods
Blood was collected after an overnight fast. Sera were
collected and stored (for 4 to 28 months) at -80°C until
assayed. Total serum ceruloplasmin concentration was
analyzed by the Department of clinical chemistry of the
University hospital Heidelberg using an immuno-nephe-
lometric assay with anti-serum to human ceruloplasmin
(Dade Behring, Marburg, Germany) on a BNII nephel-
ometer (Dade Behring, Germany) according to the man-
ufacturer’s instructions.
Serum ceruloplasmin oxidase activity with o-dianisi-
dine dihydrochloride as substrate was determined spec-
trophotometrically as described previously [10].
Statistical analysis
Variables are expressed as median with interquartile
range (IQR). The data obtained for ceruloplasmin oxi-
dase activity, immunoreactive ceruloplasmin concentra-
tion, and age are summarized as box and whisker plots.
For statistical analysis of differences between the groups
the Kruskal-Wallis-test with post-hoc testing using
Mann-Whitney U-test was used. ‘Initial presentation’
was compared between groups by Fisher’s exact test.
McNemar test was used to compare sensitivity and spe-
cificity of both ceruloplasmin assays for prediction of
presence of SMs. All calculations including generation
of receiver operating characteristics (ROC) analysis were
performed using SPSS version 16.0 (SPSS, Chicago, IL).
Two sided p-values were reported in all cases and a p-
value < 0.05 was considered statistically significant.
Results
Analysis of mutations of ATP7B
T h em o s tc o m m o nm u t a t i o nw a st h em i s s e n s ep .
H1069Q mutation, being homozygous in 30 (50.9%) and
compound heterozygous in 15 (25.4%) patients. Other
infrequent missense mutations were p.R710Q (detected
in n = 1 patients), pE754K (n = 1), p.P760L (n = 1), p.
D765N (n = 3), p.M769V (n = 1), p.R778L (n = 1), p.
T858A (n = 1), p.R919W (n = 1), p.R969Q (n = 2), p.
G982V (n = 1), p.A1063V (n = 1), p.G1099S (n = 1), p.
V1106D (n = 1). Detected nonsense mutations were p.
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The frameshift mutations detected were p.L722E-fs (n =
1), p.P767P-fs (n = 2), c.778dupC (n = 1), p.K844K-fs (n
= 2), c.del930-935 (n = 1), p.Val1217_Leu1218del (n =
2), p.I1330I-fs (n = 1), c.3402delC (n = 2), and
c.3843insT (n = 1). One splice site mutation was found
(c.1708-1G>A, n = 1)).
Of all 27 identified mutations 4 were novel. The novel
mutations included c.del930-935 (n = 1), p.I1330I-fs (n
= 1), c.3843insT (n = 1), and pE754K (n = 1).
Most mutations were detected in exons 8 (10 different
mutations) and 15 (4 different mutations). No mutation
was detected by means of direct sequencing in exons 3
to 7, 9, 11, 16, and 20. Of the 27 detected mutations in
ATP7B, 15 were classified as mild mutations (’MMs’,
missense mutations), and 12 as severe mutations (’SMs’,
frameshift/nonsense/splice site mutations).
Evaluation of the correlation of phenotype and genotype
Of the 59 patients analyzed, 39 (66.1%) had two MMs
(MM/MM), 15 (25.4%) had the genotype SM/MM, and
5 patients (8.5%) had two SMs on their ATP7B alleles
(SM/SM).
There were no statistically significant differences
between the types of mutation and the mode of initial
presentation: Of the 39 WD patients carrying only mis-
sense mutations primary clinical symptoms were neuro-
logical in 7 and hepatic in 32. Of the 15 patients with
an SM/MM genotype primary clinical symptoms were
neurological in 5 and hepatic in 10. In the five patients
with two SMs primary symptoms were neurological in 2
and hepatic in 3.
Serum ceruloplasmin levels differed significantly
between the three groups. This was true for both enzy-
matically and immunologically measured serum cerulo-
plasmin levels (P < 0.001 and P = 0.001, respectively).
The lowest levels were measured in patients with two
SMs (0.0 U/L; IQR, 0.0 - 0.0 U/L and 0.02 g/L; IQR,
0.01-0.02 g/L, respectively) and the highest in patients
with two MMs (17.8 U/L; IQR, 5.8 - 35.1 U/L and 0.11
g/L; IQR, 0.10 - 0.17 g/L, respectively) (Figure 1A and
1B).
The age of disease onset was also significantly differ-
ent between the three patient groups (P = 0.019).
Patients with two SMs manifested their disease at the
lowest age (13 years; IQR 9-13), while patients with two
MMs were oldest at disease onset (22 years; IQR 14 to
27) (Figure 2).
By ROC curve we analyzed if ceruloplasmin serum
levels predict the presence of SMs. For ROC curve ana-
lysis patients were grouped into two groups: patients
with at least one SM (n = 20) and patients with a homo-
zygous or compound heterozygous MM (n = 39). ROC
curve analysis resulted in the greatest sum of sensitivity
and specificity of serum ceruloplasmin oxidase activity
in identifying WD patients with at least one SM at a cut
point of 5 U/L, while the greatest sum of sensitivity and
specificity of immunoreactive ceruloplasmin concentra-
tions in our study cohort was obtained at a cut point of
0.09 g/L (Figure 3). For ceruloplasmin oxidase activity
the sensitivity was 80.0% (95% CI, 55.7% - 93.4%) and
the specificity was 79.5% (95% CI, 63.1% - 90.1%) at a
cut-off of ≤ 5 U/L. For immunoreactive ceruloplasmin
the sensitivity was 75.0% (95% CI, 50.6% - 90.4%), and
the specificity was 79.5% (95% CI, 63.1% - 90.1%) at a
cut-off of ≤ 0.09 g/L. The ROC curve analysis showed
that both, serum ceruloplasmin oxidase activity and
immunoreactive serum ceruloplasmin, can be used to
predict the presence of a SM. McNemar test revealed
no significant difference between both assays in predict-
ing presence of SMs, neither for sensitivity nor for
specificity.
Discussion
Although considered a useful diagnostic test in WD,
immunologically measured serum ceruloplasmin has
been shown to be in the normal range in 35% of
patients with hepatic WD [20] and a low immunologi-
cally measured serum ceruloplasmin has a positive pre-
dictive value of only 5.9% [21]. As apoceruloplasmin
may interfere with the immunologic assay but not with
the enzymatic ceruloplasmin measurement, an overesti-
mation of serum ceruloplasmin can be avoided by use
of the oxidase method for ceruloplasmin determination.
Recently we could provide evidence that serum cerulo-
plasmin oxidase activity measured enzymatically with o-
dianisidine as substrate is superior to immunoreactive
ceruloplasmin in diagnosing WD.
In our present study we analyzed if serum ceruloplas-
min oxidase levels correlate with the ATP7B genotype.
The patients were grouped according to the mutations
detected in protein truncating and missense mutations.
This grouping was based on the hypothesis that truncat-
ing and non-truncating mutation groups are likely to
h a v ead i f f e r e n ti m p a c ti nt h ef u n c t i o n a lp r o p e r t i e so f
the mutated protein. As serum ceruloplasmin levels can
increase in response to pregnancy, estrogen therapy, or
acute inflammation, patients fulfilling these criteria were
excluded from the study cohort [18,19].
For the first time we could show that serum cerulo-
plasmin oxidase activities measured enzymatically with
o-dianisidine as substrate differ significantly between
WD patients with protein-truncating and non-truncating
ATP7B mutations. In our German WD cohort of 59
patients protein-truncating mutations were associated
with significantly lower oxidase levels than missense
mutations. In addition to ceruloplasmin oxidase activ-
ities we determined immunoreactive ceruloplasmin
serum levels and could show the same relation. Our
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that were conducted in other European study cohorts:
one Greek, one Polish, and one Italian [15,16,22]. In
these studies patients with protein-truncating mutations
had lower ceruloplasmin concentrations than patients
with missense mutations. This is of note, because it aug-
ments the line of evidence for an association of protein-
truncating mutations with a more severe impairment of
holo-ceruloplasmin synthesis. It might explain normal
or borderline ceruloplasmin levels in some WD patients
as protein-truncating mutations disrupt any copper-
transporting function, while certain missense mutations
might allow residual function in holo-ceruloplasmin
synthesis.
In parallel to the effect on serum ceruloplasmin oxi-
dase activities we observed an earlier onset of WD in
patients with truncating ATP7B mutations when com-
pared to missense mutations. This finding in our Ger-
man study cohort is in accordance with two previously
published studies conducted in European cohorts, a Pol-
ish and a Greek [15,22]. However, other reports did not
find a younger age of onset in patients with truncating
mutations [16,23,24]. The effect of truncating mutations
observed in our present study might be influenced by
the p.H1069Q mutation, the most frequent mutation in
European WD patients. For this mutation an association
with a late and predominantly neurological presentation
in WD could be shown in a recent meta-analysis [11],
although the underlying studies are quite controversial
[12-14]. Thus the predominance of the homozygous
pH1069Q mutation in the MMs group in our study
cohort might have biased the ‘group effect’ seen for
MMs when compared to truncating mutations. Never-
theless, our results support the line of evidence that at
least for European WD patients an influence of the type
of mutation on the phenotype can be assumed.
Because ATP7B mutation analysis, due to the great het-
erogeneity of mutations, is quite laborious, we asked if
serum ceruloplasmin levels might allow prediction of
truncating mutations. By ROC analysis ceruloplasmin
level cut-points with the highest sum of sensitivity and
specificity for prediction of truncating mutations were
identified. At an optimal cut-point ceruloplasmin oxidase
activity allowed prediction of SMs with a sensitivity of
80% and a specificity of 79.5%. Based on this result,
mutation analysis in European WD patients might be
facilitated by considering serum ceruloplasmin oxidase
level before starting mutation analysis, as assuming the
more probable type of mutation before starting mutation
analysis might shorten the mutation identification pro-
cess. However, as discussed above, the results of ROC
analysis might only apply for European patients and not
for populations with a different mutation spectrum.
Conclusion
In conclusion, our data show that in our German study
cohort truncating ATP7B mutations were associated
with lower serum ceruloplasmin oxidase levels and an
earlier age of disease onset when compared to MMs. At
least in European populations measurement of serum
ceruloplasmin oxidase might help to predict presence of
truncating ATP7B mutations and might facilitate the
mutation analysis.
Figure 1 Serum ceruloplasmin oxidase activity and
immunoreactive serum ceruloplasmin in Wilson disease
patients grouped according to their type of ATP7B mutation.
Analysis of Wilson disease (WD) patients possessing either (1) two
‘severe’ mutations (SM/SM); (2) one ‘severe’ mutation and one
missense mutation (SM/MM), or (3) two missense mutations (MM/
MM). Distribution of data presented as box and whisker plots: 25
th
percentile, median, 75
th percentile, maximum, outliers (circles), and
extreme values (x). Both assays resulted in no indeterminate results
or missing data. a, p-value for the comparison SM/SM with SM/MM
patients; b, p-value for the comparison SM/SM with MM/MM
patients. (A) Oxidase activity is significantly lower in SM/SM patients
(0.0 U/L; IQR, 0.0 to 0.0) compared to SM/MM patients (3.1 U/L; IQR,
0.0 - 5.9) and MM/MM patients (17.8 U/L; IQR, 5.8 - 35.1). (B)
Immunoreactive serum ceruloplasmin is significantly lower in SM/
SM patients (0.02 g/L; IQR, 0.01 - 0.02) compared to SM/MM patients
(0.07, g/L; IQR 0.06 - 0.10) and MM/MM patients (0.11 g/L; IQR, 0.10 -
0.17).
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